2. Einhorn L.M., Zhan M., Hsu V.D., Walker L.D., Moen M.F., Seliger S.L., Weir M.R., Fink J.C. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 2009;169:1156–1162.

3. Sarafidis P.A., Blacklock R., Wood E., Rumjon A., Simmonds S., Fletcher-Rogers J., Ariyanayagam R., Al-Yassin A., Sharpe C., Vinen K. Prevalence and factors associated with hyperkalemiain predialysispatients followed in a low-clearance clinic. Clin. J. Am. SocNephrol. 2012;7:1234–1241.

4. Hayes J., Kalantar-Zadeh K., Lu J.L., Turban S., Anderson J.E., Kovesdy C.P. Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron. Clin. Pract. 2012;120:8–16.

5. Каюков И.Г., Куколева Л.Н., Зверьков Р.В., Эмануэль В.Л., Добронравов В.А., Смирнов А.В. Гомеостаз калия на различных стадиях хронической болезни почек. Нефрология и диализ. 2013;4:326.

6. Epstein M., Reaven N.L., Funk S.E., McGaughey K.J., Oestreicher N., Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am. J. Manag. Care. 2015;21:212–220.

7. Kovesdy C.P., Regidor D.L., Mehrotra R., Jing J., McAllister C.J., Greenland S., Kopple J.D., Kalantar-Zadeh K. Serum and dialysate potassium concentrations and survivalin hemodialysis patients. Clin. J. Am. SocNephrol. 2007;2:999–1007.

8. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N. Engl. J. Med. 2004;351:585–592.

9. Goyal A., Spertus J.A., Gosh K., Venkitachalam L., Jones P.G., Van den Berghe G., Kosiborod M. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307:157–164.

10. Сollins A.J., Reaven N., Funk S. Potassium levels and mortality in patients with CKD. J. Am. SocNephrol. 23014,25:270A.

11. Pun P.N., Lehrich R.W., Honeycutt E.F., Herzog C.A., Middleton J.P. Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. Kidney Int. 2011;79:218–227.

12. Shearer F., Lang C.C., Struthers A.D. Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin. Pharmacol. Ther. 2013;94:459–467.

13. Hsu T.W., Liu J.S., Hung S.C. Kuo K.L., Chang Y.K., Chen Y.C., Hsu C.C., Tarng D.C. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension and anemia. JAMA Intern. Med. 2014;174:347–354.

14. Xie X., Liu I., Prekovic V., Li X., Ninomiya T., Hou W., Zhao N., Liu L., Lv J., Zhang H., Wang H. Renin-angiotensin inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials

15. The CONSENSUS Trial Study Group. Effects of enalaprilon mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Eng. J. Med. 1987;316:1429–1435.

16. Шилова Е.М., Смирнова А.В., Козловской Н.Л. Нефрология. Клинические рекомендации. 2016.

17. Krum H., Shi H., Pitt B., McMurray J., Swedberg K., van Veldhuisen D.J., Vincent J., Pocock S., Zannad F. Eplerenone in patients with systolic heart failure and mild symptoms. N. Eng. J. Med. 2011;364:11–21.

18. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N. Eng. J. Med. 2004;351:1296–1305.

19. Taler S.J., Agarwal R., Bakris G.L. Flynn J.T., Nilsson P.M., Rahman M., Sanders P.W., Textor S.C., Weir M.R., Townsend R.R. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am. J. Kidney Dis. 2013;62:201–213.

20. Yildirim T., Arici M., Piskinpasa S., Aybal-Kutlugun A., Yilmaz R., Altun B., Erdem Y., Turgan C. Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren. Fail. 2012;34:1095–1099.

21. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R. For the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibitions versus enalapril in heart failure. N. Engl. J. Med. 2014,371:993–1004.

22. US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.

23. Jadoul M., Thumma J., Fuller D.S., Tentori F., Li Y., Morgenstern H., Mendelssohn D., Tomo T., Ethier J., Port F.., Robinson B.M. Modifiable practices associated with sudden death among hemodialysis patients in the dialysis outcomes and practice pattern study. Clin. J. Am. Soc. Nephrol. 2012;7:765–774.

24. Palmer B.F. Regulation of potassium homeostasis. Clin. J. Am. SocNephrol. 2015;10:1050–1060.

25. Samson S.C., Welling P.A. Two channels for one job. Kidney Int. 2007;72:529–530.

26. Giebish G., Krapf R., Wagner C. Renal and extrarenal regulation of potassium. Kidney Int. 2007;72:397–410.

27. Rabinowitz L., Green D.M., Sarason R.L., Yamauchi H. Homeostatic potassium excretion in fed and fasted sheep. Am. J. Physiol. 1988;254:357–380.

28. Calo L., Borsatti A., Favaro S., Rabinovitz L. Kaliuresis in normal subject following oral potassium citrate intake without increased plasma potassium concentration. Nephrol. 1995;69:253–258.

29. Preston R.A., Afshartous D., Rodco R., Alonso A.B., Garg D. Evidence for a gastrointestinal kaliuretic signaling axis in humans. Kidney Int. 2015;88:1383–1391.

30. Tsuchiya Y., Nakashima S., Banno Y., Suzuki Y., Morita H. Effect of high-NaCl or high-KCl diet on hepatic Na+ and K+ receptor sensitivity and NKCC1 expression in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004;286:R591–R596.

31. Lee F.N., Oh G., McDonough A.A., Youn J.H. Evidence for gut factor in K homeostasis. Am. J. Physiol. Renal. Physiol. 2007;293:F541–F547.

32. Oh K.S., Oh Y.T., Kim S.V., Kita T., Kang I., Youn J.H. Cut sensing of dietary K+ intake increases renal K+ excretion. Am. J. Physiol. Regul. Integr. Comp.Physiol. 2011;301:R421–R429.

33. El Mogharabi S., Houillier P., Picard N., Sohet F., Wootla B., Bloch-Faure M., Leviel F., Cheval L., Frische S., Meneton P., Eladari D., Chambrey R. Tissue kallikrein permits early renal adaptation to potassium load. Proc. Natl. Acad. Sci. USA 2010;107:13526–13531.

34. Susa K., Sohara E., Isobe K., Chiga M., Rai T., Sasaki S., Uchida S. WNK-OSR1/SPAK-NCC signal cascade has circadian rhythm dependent on aldosterone. Biochem. Biophys. Res. Commun. 2012;427:743–747.

35. Zuber A.M., Centeno G., Pradervand S., Nikolaeva S., Maquelin L., Cardinaux L., Bonny O., Firsov D. Molecular clock is involved in predictive circadian adjustment of renal function. Proc Natal. 2009;106(38):16523–16528.

36. Sandle G.I., Geiger E., Tapster S., Goodship T.H. Evidence for large intestinal control of potassium homeostasis in uraemic patients undergoing long-term dialysis. Clin. Sci. (Lond).1987;73:247–252.

37. Meng Q.H., Wagar E.A. Pseudohyperkalemia: a new twist on an old phenomenon. Crit. Rev. Clin. Lab. Sci. 2015;52:45–55.

38. Seimiya M., Yoshida T., Sawabe Y., Sogawa K., Umemura H., Matsushita K., Nomura F. Reducing the incidence of pseudohyperkalemia by avoiding making a fist during phlebotomy: a quality improvement report. Am. J. Kidney Dis. 2010;56:686–692.

39. Bailey I.R., Thurlow V.R. Is suboptimal phlebotomy technique impacting on potassium results for primary care? Ann. Clin. Biochem. 2008;45:266–269.

40. Parham W.A., Mehdirad A.A., Biermann K.M., Fredman C.S. Hyperkalemia revisited. Tex. Heart. Inst. J. 2006;33:40–47.

41. Mattu A., Brady W.J., Robinson D.A. Electrocardiographic manifestations of hyperkalemia. Am. J. Emerg. Med. 2000;18:721–729.

42. Wrenn K.D., Slovis C.M., Slovis B.S. The ability of physicians to predict hyperkalemia from the ECG. Ann. Emerg. Med. 1991;20:1229–1232.

43. Martinez-Vea A., Bardaji A., Garcia C., Oliver J.A. Severe hyperkalemia with minimal electrocardiographic manifestations: a report of seven cases. J. Electrocardiol. 1999;32:45–49, 31–34.

44. Green D., Green H.D., New D.I., Kalra P.A. The clinical significance of hyperkalaemia associated repolarization abnormalities in end-stage renal disease. Nephrol. Dial. Transplant. 2013;28:99–105.

45. Barold S.S., Herweg B. The effect of hyperkalaemia on cardiac rhythm devices. Europace. 2014;16:467–476.